{"id":46236,"date":"2022-07-15T15:02:25","date_gmt":"2022-07-15T13:02:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/"},"modified":"2022-07-15T15:02:25","modified_gmt":"2022-07-15T13:02:25","slug":"cintas-corporation-added-to-the-ftse4good-index","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/","title":{"rendered":"Cintas Corporation Added to the FTSE4Good Index"},"content":{"rendered":"
\n

\nA leader in the North American business services industry was recently added to one of the premier tradable global sustainability index funds<\/i>\n<\/p>\n

CINCINNATI–(BUSINESS WIRE)–$CTAS<\/a>–Cintas Corporation (Nasdaq: CTAS) has been included on the FTSE4Good Index<\/a>.\n<\/p>\n

<\/a><\/p>\n

\nCreated by the global index and data provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. The FTSE4Good indexes are used by a wide variety of market participants to create and assess responsible investment funds and other products.\n<\/p>\n

\nFTSE Russell evaluations are based on performance in areas such as Corporate Governance, Health & Safety, Anti-Corruption and Climate Change. Businesses included in the FTSE4Good Index Series meet a variety of environmental, social and governance criteria.\n<\/p>\n

\n\u201cWith our company\u2019s deep history rooted in sustainable practices, we\u2019re proud to be recognized by FTSE Russell with inclusion on their FTSE4Good Index,\u201d said Mike Hansen, Cintas Executive Vice President and Chief Financial Officer. \u201cWe hope this further demonstrates the tremendous value we create for our shareholders, customers and employee-partners as we focus on conducting our business the right way.\u201d\n<\/p>\n

\n\u201cOur inclusion on the FTSE4Good Index is certainly a welcome acknowledgement of our ongoing efforts to operate our business in a sustainable, ethical manner,\u201d said Christy Nageleisen, Cintas Vice President of ESG and Chief Compliance Officer. \u201cWe\u2019re just getting started on our formal ESG Journey, and gaining recognition for the work and accomplishments we\u2019ve made to date is motivation to continue our work as we strive for greater positive impacts in environmental, social and governance areas.\u201d\n<\/p>\n

\nIn its most recent evaluation, Cintas rated above the average of its peers in FTSE Russell\u2019s Business Support Services industry subsector for ESG Rating, Environment, Social and Governance, and was substantially higher than the average for the companies included in FTSE Russell\u2019s broader Industrials industry in all four categories. Further, Cintas earned FTSE\u2019s highest score for governance.\n<\/p>\n

\nCintas was rated especially high against the Business Support Services subindustry in Managing Climate Change, Water Security, Health & Safety, Social Supply Chain and Anti-Corruption Issues.\n<\/p>\n

\nESG at Cintas<\/b>\n<\/p>\n

\nCintas\u2019 sustainable business model has underpinned the company\u2019s growth strategy and imparted a holistic \u201cReduce, Reuse, Recycle\u201d mentality throughout the company\u2019s operations.\n<\/p>\n

\nThis approach dates back to the company\u2019s origins almost 100 years ago during the Great Depression. Out-of-work circus performers Doc and Amelia Farmer went around to Cincinnati-area businesses and collected their dirty, discarded shop rags from their trash bins, and brought the dirty rags home to launder them. When the rags were clean, Doc and Amelia then sold them back to area businesses, thereby extending their useful lives and reducing companies\u2019 ongoing need to replace their discarded rags with brand-new rags.\n<\/p>\n

\nSince then, the company has grown and expanded business operations to include uniform and apparel rental programs, facility services, first aid and safety products and services, and fire protection services.\n<\/p>\n

\nCintas\u2019 cultural focus on its Principal Objective, its Corporate Character and Management Systems \u2013 defined by Founder Dick Farmer in his book, \u201cSpirit is the Difference<\/a>\u201d \u2013 has resulted in ESG-centric business practices<\/a> embedded holistically into Cintas\u2019 operations from its start.\n<\/p>\n

\nTo learn more about Cintas\u2019 ESG program, including its most recent reporting, visiting cintas.com\/esg<\/a>.\n<\/p>\n

\nAbout Cintas Corporation<\/b>\n<\/p>\n

\nCintas Corporation helps more than one million businesses of all types and sizes get Ready\u2122<\/sup><\/b> to open their doors with confidence every day by providing products and services that help keep their customers\u2019 facilities and employees clean, safe, and looking their best. With offerings including uniforms, mats, mops, restroom supplies, first aid and safety products, fire extinguishers and testing, and safety training, Cintas helps customers get Ready for the Workday\u00ae<\/sup><\/b>. The company is also the creator of the Total Clean Program\u2122<\/sup> \u2014 a first-of-its-kind service that includes scheduled delivery of essential cleaning supplies, hygienically clean laundering, and sanitizing and disinfecting products and services. Headquartered in Cincinnati, Cintas is a publicly held Fortune 500 company traded over the Nasdaq Global Select Market under the symbol CTAS and is a component of both the Standard & Poor\u2019s 500 Index and Nasdaq-100 Index. For more information, visit cintas.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nLizz Summers, Director of Corporate Affairs | (513) 972-2859
\n
J. Michael Hansen, Executive Vice President and Chief Financial Officer | 513-972-2079
\n
Paul F. Adler, Vice President – Cintas Treasurer & Investor Relations | 513-972-4195\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

A leader in the North American business services industry was recently added to one of the premier tradable global sustainability index funds CINCINNATI–(BUSINESS WIRE)–$CTAS–Cintas Corporation (Nasdaq: CTAS) has been included on the FTSE4Good Index. Created by the global index and data provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46236","6":"format-standard","7":"category-industry"},"yoast_head":"\nCintas Corporation Added to the FTSE4Good Index - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cintas Corporation Added to the FTSE4Good Index - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"A leader in the North American business services industry was recently added to one of the premier tradable global sustainability index funds CINCINNATI–(BUSINESS WIRE)–$CTAS–Cintas Corporation (Nasdaq: CTAS) has been included on the FTSE4Good Index. Created by the global index and data provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-15T13:02:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220715005074\/en\/1395998\/21\/Cintas_Logo_-_Ready_for_the_Workday.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cintas-corporation-added-to-the-ftse4good-index\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cintas-corporation-added-to-the-ftse4good-index\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Cintas Corporation Added to the FTSE4Good Index\",\"datePublished\":\"2022-07-15T13:02:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cintas-corporation-added-to-the-ftse4good-index\\\/\"},\"wordCount\":738,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cintas-corporation-added-to-the-ftse4good-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005074\\\/en\\\/1395998\\\/21\\\/Cintas_Logo_-_Ready_for_the_Workday.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cintas-corporation-added-to-the-ftse4good-index\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cintas-corporation-added-to-the-ftse4good-index\\\/\",\"name\":\"Cintas Corporation Added to the FTSE4Good Index - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cintas-corporation-added-to-the-ftse4good-index\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cintas-corporation-added-to-the-ftse4good-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005074\\\/en\\\/1395998\\\/21\\\/Cintas_Logo_-_Ready_for_the_Workday.jpg\",\"datePublished\":\"2022-07-15T13:02:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cintas-corporation-added-to-the-ftse4good-index\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cintas-corporation-added-to-the-ftse4good-index\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cintas-corporation-added-to-the-ftse4good-index\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005074\\\/en\\\/1395998\\\/21\\\/Cintas_Logo_-_Ready_for_the_Workday.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220715005074\\\/en\\\/1395998\\\/21\\\/Cintas_Logo_-_Ready_for_the_Workday.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/cintas-corporation-added-to-the-ftse4good-index\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cintas Corporation Added to the FTSE4Good Index\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cintas Corporation Added to the FTSE4Good Index - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/","og_locale":"en_US","og_type":"article","og_title":"Cintas Corporation Added to the FTSE4Good Index - Pharma Trend","og_description":"A leader in the North American business services industry was recently added to one of the premier tradable global sustainability index funds CINCINNATI–(BUSINESS WIRE)–$CTAS–Cintas Corporation (Nasdaq: CTAS) has been included on the FTSE4Good Index. Created by the global index and data provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-15T13:02:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220715005074\/en\/1395998\/21\/Cintas_Logo_-_Ready_for_the_Workday.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Cintas Corporation Added to the FTSE4Good Index","datePublished":"2022-07-15T13:02:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/"},"wordCount":738,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220715005074\/en\/1395998\/21\/Cintas_Logo_-_Ready_for_the_Workday.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/","url":"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/","name":"Cintas Corporation Added to the FTSE4Good Index - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220715005074\/en\/1395998\/21\/Cintas_Logo_-_Ready_for_the_Workday.jpg","datePublished":"2022-07-15T13:02:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220715005074\/en\/1395998\/21\/Cintas_Logo_-_Ready_for_the_Workday.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220715005074\/en\/1395998\/21\/Cintas_Logo_-_Ready_for_the_Workday.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/cintas-corporation-added-to-the-ftse4good-index\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Cintas Corporation Added to the FTSE4Good Index"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46236"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46236\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}